Drug Profile
Research programme: anti-influenza monoclonal antibody - iBio
Alternative Names: Influenza antibody product candidate - iBio/Fraunhofer; Influenza monoclonal antibody - iBio/FraunhoferLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fraunhofer USA Center for Molecular Biotechnology; iBio Inc
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype; Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral)
- 11 Aug 2015 iBio receives patent allowance for anti-influenza monoclonal antibody in USA